The Cell Analysis Market across the globe is witnessing significant growth due to factors such as increasing corporate and government funding for cell-based research, rising incidence of chronic and infectious diseases, growing healthcare industry and medical spending, rising incidence of cancer, and introduction of technologically advanced products. Key players are focusing on providing innovative products which will lead to effective cell analysis, in less time. With this view, companies are focusing on new product launches, and partnerships, collaborations, acquisitions to attain a leadership position in the market.
The cell analysis instruments market includes microscopes, flow cytometers, spectrophotometers, qPCR, cell counters, high-content screening (HCS) systems, and cell microarrays. Among all these instruments, qPCR showcases a lucrative growth potential and represents a new revenue generating pocket for the cell analysis market. High growth in this market is attributed to its wide application of qualitative reverse transcriptase polymerase chain reaction (qRT-PCR) pharmacological drug discovery process. Currently, qPCR is being used in single-cell analysis; it helps to measure the gene expression in a single cell. Furthermore, increasing government support for cell based drug research in terms of grants and funding will enable research laboratories to opt for advanced products such as qPCR, high content screening systems, & flow cytometer which is another major reason for growth of this market.
The cell analysis market, by process is segmented into cell identification, cell viability, cell proliferation, cell structure study (cytology), cell signaling pathway/signal transduction, cell counting and quality control, target identification and validation, and single-cell analysis. The single cell analysis market is poised to witness the highest growth rate in the cell a market. The high growth in this market is attributed to the growing need to understand the functioning of cells at the individual level.
In the coming five years, growth in the cell analysis market is likely to be centered at the Asia-Pacific region. The growth in this region can be attributed to substantial budget allocations for developing the biotechnology sector by governments in various Asian countries. For instance, The Global Health Innovative Technology Fund (GHIT Fund) is a public-private partnership dedicated towards Japanese R&D focusing on research related to infectious diseases. It offers funds to various partnerships between Japanese and non-Japanese organizations, which include various pharmaceutical companies, academic and research institutions, and product development partnerships (PDPs).